Preferred Sample Type
Suitable Specimen Types
- Serum
Specimen Transport
1st class post overnight to referral laboratoryTurnaround Time
28 days from receipt in referral laboratoryVedolizumab Drug level
General Information
Vedolizumab is Gut selective Integrin blocker used in the treatment of inflammatory bowel diseases such as Crohn's disease and Ulcerative colitis. Unlike other biologics used to treat these conditions such as anti TNF alpha drugs, Vedolizumab is selective fro the gut and so has less systemic side effects.
Trough levels of the drug may give an indication as to the possible outcome of the treatment as higher levels of drug during induction are associated with better clnical and endoscopic outcome.
Low level of the drug can also indicate treatment failure, and when this falls below the detectable range anti drug antibodies may be measured.
Patient Preparation
Sample should be taken prior to infusion
Reference Range
37.1 mg/L at week 6
18.4 mg /L at week 14
12.7 mg/L during maintenance treatment.
Source of Reference Range
Provided by referral laboratorySpecifications
- EQA Scheme?: Yes
- EQA Status: Sample exchange scheme in place